发布求助
文献互助 智能选刊 最新文献

Future drug discovery最新文献

筛选
英文 中文
Widened scope of drug repurposing/chiral switches, elements of secondary pharmaceuticals: the quinine/quinidine case 扩大药物再利用/手性转换的范围，二次制药的要素：奎宁/奎尼丁案例
Future drug discovery Pub Date : 2024-02-20 DOI: 10.4155/fdd-2023-0006
Ilaria D’Acquarica, Israel Agranat
{"title":"Widened scope of drug repurposing/chiral switches, elements of secondary pharmaceuticals: the quinine/quinidine case","authors":"Ilaria D’Acquarica, Israel Agranat","doi":"10.4155/fdd-2023-0006","DOIUrl":"https://doi.org/10.4155/fdd-2023-0006","url":null,"abstract":"Drug repurposing to new medical uses and chiral switches are elements of secondary pharmaceuticals. This article focuses on drug repurposing/chiral switches of the diastereomeric quasi-enantiomeric antimalarial quinine and antiarrhythmic quinidine, based on the histories of these drugs (1638–2022), applying a widened scope. Quinine, an essential medicine, changed the world. Drug repurposing is a strategy for identifying new uses for approved or investigational drugs outside the scope of the original medical indications. Potential drugs are not included in the definition of drug repurposing. Drug repurposing may be within or outside the therapeutic group, e.g., quinidine to quinine repurposing, from treatment of arrhythmia or severe malaria to uncomplicated malaria. The scope of chiral switches included racemate to single enantiomer and other switches of the status of chirality, e.g., racemate and quasi-racemate to scalemic mixtures. There are 16 quinine/quinidine stereoisomers. Given the multiple pharmacological activities of Cinchona alkaloid stereoisomers, this article calls for subjecting them to comprehensive drug repurposing/chiral switch searches for new medical uses.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"540 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140448167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Codeine dysregulates ribosome biogenesis in Escherichia coli with DNA double-strand breaks to chart path to new classes of antibiotics 可待因在大肠杆菌DNA双链断裂中失调核糖体的生物发生，为开发新型抗生素指明了道路
Future drug discovery Pub Date : 2023-10-11 DOI: 10.4155/fdd-2023-0005
Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur
{"title":"Codeine dysregulates ribosome biogenesis in <i>Escherichia coli</i> with DNA double-strand breaks to chart path to new classes of antibiotics","authors":"Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur","doi":"10.4155/fdd-2023-0005","DOIUrl":"https://doi.org/10.4155/fdd-2023-0005","url":null,"abstract":"Aim: A bacterial genetics-guided approach was utilized for the discovery of new compounds affecting bacterial genome stability. Materials &amp; methods: Fungal extracts and fractions were tested for genome instability-mediated antibacterial activity. Interaction assays and RT-qPCR were used to identify compounds that boost the activity of sub-minimum inhibitory concentration streptomycin and obtain insights on the molecular mechanisms of the primary hit compound, respectively. Results: Several extracts and fractions caused bacterial genome instability. Codeine, in synergy with streptomycin, regulates double-strand break (DSB) repair and causes bacterial ribosome dysfunction in the absence of DSBs, and dysregulation of ribosome biogenesis in a DSB-dependent manner. Conclusion: This study demonstrates a potential viable strategy that we are exploring for the discovery of new chemical entities with activities against Escherichia coli and other bacterial pathogens.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136062471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PepFun 2.0: improved protocols for the analysis of natural and modified peptides PepFun 2.0:改进了天然肽和修饰肽的分析方案
Future drug discovery Pub Date : 2023-08-24 DOI: 10.4155/fdd-2023-0004
R. Ochoa
{"title":"PepFun 2.0: improved protocols for the analysis of natural and modified peptides","authors":"R. Ochoa","doi":"10.4155/fdd-2023-0004","DOIUrl":"https://doi.org/10.4155/fdd-2023-0004","url":null,"abstract":"Aim: The role of peptides is nowadays relevant in fields, such as drug discovery and biotechnology. Computational analyses are required to study their properties and gain insights into rational design strategies. Materials & methods: PepFun 2.0 is a new version of the python package for the study of peptides using a set of modules to analyze the sequence and structure of the molecules. Both natural and modified peptides containing non-natural amino acids can be studied based on the provided functionalities. Results: PepFun 2.0 comprises five main modules for tasks such as sequence alignments, prediction of properties, generation of conformers, detection of interactions and extra functions to include peptides containing non-natural amino acids. Conclusion: The code, tutorial and specific examples are open source and available at: https://github.com/rochoa85/PepFun2 .","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45896506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a novel chemoinformatic tool for natural product databases 一种新型天然产物数据库化学信息学工具的开发
Future drug discovery Pub Date : 2023-06-01 DOI: 10.4155/fdd-2023-0007
Paulo Ricardo Viviurka do Carmo, Ricardo Marcacini, Marilia Valli, João Victor Silva-Silva, Leonardo Luiz Gomes Ferreira, Alan Cesar Pilon, Vanderlan da Silva Bolzani, Adriano D Andricopulo, Edgard Marx
{"title":"Development of a novel chemoinformatic tool for natural product databases","authors":"Paulo Ricardo Viviurka do Carmo, Ricardo Marcacini, Marilia Valli, João Victor Silva-Silva, Leonardo Luiz Gomes Ferreira, Alan Cesar Pilon, Vanderlan da Silva Bolzani, Adriano D Andricopulo, Edgard Marx","doi":"10.4155/fdd-2023-0007","DOIUrl":"https://doi.org/10.4155/fdd-2023-0007","url":null,"abstract":"Aim: This study aimed to develop a chemoinformatic tool for extracting natural product information from academic literature. Materials &amp; methods: Machine learning graph embeddings were used to extract knowledge from a knowledge graph, connecting properties, molecular data and BERTopic topics. Results: Metapath2Vec performed best in extracting compound names and showed improvement over evaluation stages. Embedding Propagation on Heterogeneous Networks achieved the best performance in extracting bioactivity information. Metapath2Vec excelled in extracting species information, while DeepWalk and Node2Vec performed well in one stage for species location extraction. Embedding Propagation on Heterogeneous Networks consistently improved performance and achieved the best overall scores. Unsupervised embeddings effectively extracted knowledge, with different methods excelling in different scenarios. Conclusion: This research establishes a foundation for frameworks in knowledge extraction, benefiting sustainable resource use.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135143751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computational approaches to targeting protein–protein interactions in cancer: a pathway to drug discovery 针对癌症中蛋白质-蛋白质相互作用的计算方法:药物发现的途径
Future drug discovery Pub Date : 2023-05-05 DOI: 10.4155/fdd-2023-0003
M. Okereke, K. David, O. Adedeji
{"title":"Computational approaches to targeting protein–protein interactions in cancer: a pathway to drug discovery","authors":"M. Okereke, K. David, O. Adedeji","doi":"10.4155/fdd-2023-0003","DOIUrl":"https://doi.org/10.4155/fdd-2023-0003","url":null,"abstract":"","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies. 单独与联合：目前针对谷氨酰胺酶的方法，作为抗癌疗法的一部分。
Future drug discovery Pub Date : 2023-03-01 Epub Date: 2023-03-27 DOI: 10.4155/fdd-2022-0011
Thuy-Tien T Nguyen, William P Katt, Richard A Cerione
{"title":"Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies.","authors":"Thuy-Tien T Nguyen, William P Katt, Richard A Cerione","doi":"10.4155/fdd-2022-0011","DOIUrl":"10.4155/fdd-2022-0011","url":null,"abstract":"<p><p>Metabolic reprogramming is a major hallmark of malignant transformation in cancer, and part of the so-called Warburg effect, in which the upregulation of glutamine catabolism plays a major role. The glutaminase enzymes convert glutamine to glutamate, which initiates this pathway. Inhibition of different forms of glutaminase (KGA, GAC, or LGA) demonstrated potential as an emerging anti-cancer therapeutic strategy. The regulation of these enzymes, and the molecular basis for their inhibition, have been the focus of much recent research. This review will explore the recent progress in understanding the molecular basis for activation and inhibition of different forms of glutaminase, as well as the recent focus on combination therapies of glutaminase inhibitors with other anti-cancer drugs.</p>","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"4 4","pages":"FDD79"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/98/fdd-04-79.PMC10051075.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10119513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting immune checkpoint pathways in melanoma: triumphs and challenges 靶向黑色素瘤免疫检查点途径：成功与挑战
Future drug discovery Pub Date : 2023-03-01 DOI: 10.4155/fdd-2022-0010
P. Back, Kaitlin Rascon, Md. Rakibul Islam, Christopher Selby, N. M. La‐Beck
{"title":"Targeting immune checkpoint pathways in melanoma: triumphs and challenges","authors":"P. Back, Kaitlin Rascon, Md. Rakibul Islam, Christopher Selby, N. M. La‐Beck","doi":"10.4155/fdd-2022-0010","DOIUrl":"https://doi.org/10.4155/fdd-2022-0010","url":null,"abstract":"The immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma by significantly increasing survival rates, with the promise of durable disease remission in some patients. Herein we review the role of immune checkpoints in melanoma; the history of melanoma immunotherapy; pivotal clinical trial data for ipilimumab, pembrolizumab, nivolumab and relatlimab; and the current clinical role of each ICI. We discuss the challenges that accompany these triumphs in the treatment of melanoma, including: how to distinguish between responders and nonresponders; how to optimize ICI dosing and combinatorial approaches; and the best practices for monitoring response and managing immune-related toxicities. We offer our perspective on the financial toxicity of ICIs and new developments that could deliver answers to current challenges.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43220195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miRNA-205: a future therapeutic molecule for liver diseases. miRNA-205:未来肝脏疾病治疗分子
Future drug discovery Pub Date : 2023-01-01 DOI: 10.4155/fdd-2022-0012
Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu
{"title":"miRNA-205: a future therapeutic molecule for liver diseases.","authors":"Marco Cabrera,&nbsp;Meghana Kolli,&nbsp;Meena Jaggi,&nbsp;Subhash C Chauhan,&nbsp;Murali M Yallapu","doi":"10.4155/fdd-2022-0012","DOIUrl":"https://doi.org/10.4155/fdd-2022-0012","url":null,"abstract":"study results suggest that miR-205 / NEU1 can be a viable therapeutic target for treatment of NAFLD. In the series of experiments conducted on mouse models, it was found that miR-205 has an effect on transcription factor ZEBI, which has a role in liver metabolism and insulin resistance [20] . On the other hand, when NZ10 mice were predisposed with obesity, Type 2 diabetes and hepatic steatosis; fed with high protein fish oil diet and examined for the biochemical and physical functions, results showed that the diet prevented steatosis and reduced serum cholesterol and triglycerides","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"4 3","pages":"FDD78"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/d0/fdd-04-78.PMC9990095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Shedding light on the dark genome: drugging long non-coding RNA 揭开黑暗基因组的面纱：对长的非编码RNA进行麻醉
Future drug discovery Pub Date : 2022-07-15 DOI: 10.4155/fdd-2022-0009
Stefan Schiesser, Werngard Czechtizky, R. J. Cox
{"title":"Shedding light on the dark genome: drugging long non-coding RNA","authors":"Stefan Schiesser, Werngard Czechtizky, R. J. Cox","doi":"10.4155/fdd-2022-0009","DOIUrl":"https://doi.org/10.4155/fdd-2022-0009","url":null,"abstract":"","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42013261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming the shortcomings of peptide-based therapeutics 克服基于肽的治疗方法的缺点
Future drug discovery Pub Date : 2022-07-11 DOI: 10.4155/fdd-2022-0005
C. Lamers
{"title":"Overcoming the shortcomings of peptide-based therapeutics","authors":"C. Lamers","doi":"10.4155/fdd-2022-0005","DOIUrl":"https://doi.org/10.4155/fdd-2022-0005","url":null,"abstract":"Peptides have traditionally been perceived as poor drug candidates due to unfavorable characteristics mainly regarding their pharmacokinetic behavior, including plasma stability, membrane permeability and circulation half-life. Nonetheless, in recent years, general strategies to tackle those shortcomings have been established, and peptides are subsequently gaining increasing interest as drugs due to their unique ability to combine the advantages of antibodies and small molecules. Macrocyclic peptides are a special focus of drug development efforts due to their ability to address so called ‘undruggable’ targets characterized by large and flat protein surfaces lacking binding pockets. Here, the main strategies developed to date for adapting peptides for clinical use are summarized, which may soon help usher in an age highly shaped by peptide-based therapeutics. Nonetheless, limited membrane permeability is still to overcome before peptide therapeutics will be broadly accepted.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46169376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信